Survivin, a novel member of the IAP (inhibitor of apoptosis) protein family, is associated with malignant transformation and is overexpressed in human brain cancers. On this basis, we hypothesized that the human survivin promoter may be an excellent candidate for glioma gene therapy by transcriptional targeting. To that end, we compared three recombinant adenoviral vectors (reAds), reAdGL3BCox-2, reAdGL3BMidkine, and reAdGL3BSurvivin, in which the reporter gene luciferase is driven by the Cox-2, Midkine, or surivin promoter, respectively, in glioma cell lines and primary glioma cells. The data showed the survivin promoter exhibited the highest activity among the three reAd vectors in both established and primary glioma cells. We also compared the survivin promoter activity between in D65 glioma tumor cells and in normal non-transformed astrocytes. The results indicate there is 6-12 fold higher activity in tumor cells than in the astrocytes. Also, the survivin promoter is down regulated in human brain tissue compared to the cytomegalovirus promoter. Next, the conditionally replicating adenoviral vector (CRAd), CRAd-Survivin-RGD, in which the Ad E1 gene is driven by the survivin promoter, and the Ad infectivity is enhanced by capsid modification with RGD, was seen to efficiently kill the multiple established glioma tumor cells (oncolysis). These CRAd agents driven by the survivin promoter were further shown to efficiently replicate in both the glioma cells (D65) and in U118MG xenografts both in vitro and in vivo. Also we observed the anti-tumor effects of the CRAd agents in an animal model. The tumor growth was inhibited more than 60% by i.t. injection of CRAd-Survivin agents. In conclusion, the survivin promoter is a promising tumor-specific promoter for transcriptional targeting based on its activation in glioma cells, efficient reporter gene expression, adenoviral replication in gliomas and repression in normal cells. This promoter has a |[ldquo]|tumor on|[rdquo]| and |[ldquo]|normal tissue off|[rdquo]| profile, an important parameter for cancer gene therapy. To that end, therapeutic vectors based on this approach may translate into treatment of human gliomas in the clinic.